NB Capital

About The Fund

NB Capital is an investment firm based in Copenhagen, Denmark, primarily focused on healthcare, specifically in all phases of pharmaceutical drug development and commercial enterprises. Their approach combines risk aversion with innovation, targeting opportunities across public and private equity markets globally. They manage discretionary capital approximately totaling 1 billion USD, attracting a diverse investor base that includes institutional investors, sovereign wealth funds, and family offices. Their investment thesis revolves around the complex and challenging biopharmaceutical sector which boasts an annual revenue exceeding one trillion USD globally. This sector, while offering significant potential rewards, also presents intricate risks which NB Capital navigates with over 25 years of cumulative investment experience and a specialized expert team. Their strategy is to identify low-risk investments which present considerable upside within a 2-3 year time frame, in keeping with each investor’s risk tolerance. This strategy has been authenticated by multi-year performance records with large investors already possessing beta-exposure in global equities. NB Capital's methodology is designed to strategically utilize the overload of global information, biased incentives, and market irrationalities, which they have refined over two and a half decades. Their past investments display an engagement in various investment types, including seed investments, early public offerings, and acting as a pro-management activist public investor. Significant involvements include roles as the co-founder of Genmab A/S and seed investor in BioMarin Pharmaceutical Inc, along with numerous other endeavors within the biotech and life science industries. The firm's CEO, Florian Schönharting, has been integral in these investments through NB Capital or in his previous role in asset management. NB Capital also shows a commitment to nurturing talent within their field, seeking highly qualified individuals to join their team for medical and scientific due diligence work.